Dimerix Limited · ASX:DXB
Dimerix — Gold Coast Investment Showcase 2018
17 slides from Dimerix's conference presentation, Jun 20, 2018
Slide 1: DMX-200 for Chronic Kidney Disease
For personal use only Dimerix DMX-200 for Chronic Kidney Disease Gold Coast Investment Showcase 20 June 2018 ASX: DXB 1
Slide 2: Disclaimer
Disclaimer For personal use only S o m e o f th e in fo rm a tio n in th is p re s e n ta tio n m a y re fe r to D im e rix L im ite d (“D im e rix ” o r th e “C o m p a n y ”) b a se d o n in fo rm a tio n a va ila b le to it a s a t th e d a te o f th is p re se n ta tio n . T h e in fo rm a tio n
Slide 3: Dimerix Limited (ASX:DXB)
Dimerix Limited (ASX:DXB) For personal use only Dimerix has 2 Phase 2 clinical trial programs starting recruiting in Q3 CY2018 1. DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) • Phase 2a US Orphan drug designation achieved - path to US drug registration • Reduced risk of adverse safety event
Slide 4: Corporate overview
Corporate overview For personal use only Corporate snapshot Share price history ASX code: DXB# Share price (13 June 18): $0.105 Market cap: $16.3m Cash (30 Mar 2018): $7.55m Shares on issue* 155m # Consolidation (20:1) completed 31 st October 2017 *Unlisted Performance Shares: 3.75.m; Options (ESOP)
Slide 5: What is DMX-200?
What is DMX-200? For personal use only • DMX-200 is an adjunct therapy. We administer two existing, well known drugs, to achieve a synergistic effect • The two drugs used are: • Propagermanium – CCR2 antagonist with decades of use in Japan for chronic Hepatitis B • Irbesartan – existing standard of
Slide 6: Chronic kidney disease (CKD)
Chronic kidney disease (CKD) For personal use only • CKD is a growing global health problem affecting over 10% of the population • Damaged kidneys “leak” proteins into the urine. This is called proteinuria. • Proteinuria is the most common symptom of the disease and is the strongest prognostic indic
Slide 7: Current Treatments
Current Treatments For personal use only • First line therapy is the use of drugs to reduce blood pressure, which can reduce proteinuria but do not stop progressive kidney failure • In some types of kidney disease (eg FSGS), patients are W ill in re m iss io n given a cocktail of drugs including imm
Slide 8: Market value of lead clinical programs – DMX-200 for FSGS and DKD
Market value of lead clinical programs – DMX-200 for FSGS and DKD For personal use only Focal segmental glomerulosclerosis (FSGS) Diabetic Kidney Disease (DKD) • FSGS is a very serious disease and is • DKD is the single most common cause of CKD characterized by rapid progression to end- worldwide an
Slide 9: Market value – DMX-200
Market value – DMX-200 For personal use only Comparable companies in the US with developments in FSGS are capitalised at more than $500 million 9
Slide 10: Compelling data for DMX-200 from the Phase 2a Trial
Compelling data for DMX-200 from the Phase 2a Trial For personal use only • When introduced, the current standard of care medication (irbesartan) was a step change in Diabetic proteinuria mean reduction 35.6% n=10 the treatment of chronic kidney disease patients • In 2001 irbesartan was studied in a
Slide 11: DMX-200: FSGS and DKD studies to be conducted in parallel
DMX-200: FSGS and DKD studies to be conducted in parallel For personal use only • Both trials are randomised, double blind placebo-controlled, crossover studies • “Crossover” trial design means that all patients receive both placebo and DMX-200 on the trials, in randomised order • These studies will
Slide 12: DMX-200 Timelines
DMX-200 Timelines Completed activities For personal use only Activity 2015 2016 2017 H1 2018 H2 2018 H1 2019 H2 2019 2020 Phase 2a CKD “all comers” study FSGS + DKD CRO appointment, ethics submissions, lead site Phase 2a in FSGS Phase 2b in DKD Orphan Drug Designation US Europe Regulatory Authority
Slide 13: Significant milestones
Significant milestones For personal use only DMX-200 for FSGS and DKD ü Ongoing – Partnering discussions for FSGS and DKD ü CY18Q2 – Principal Investigator and CRO engaged for ACTION studies q CY18Q2 – Ethics applications for ACTION studies q CY18Q3 – Sites open and commencement of patient recruitme
Slide 14: DMX-200 Intellectual Property – a licencing opportunity
DMX-200 Intellectual Property – a licencing opportunity For personal use only • Dimerix has granted patents in the USA, Australia and Japan covering our lead program DMX-200 (US patent no. 9,314,450); and pending applications in Europe and other major jurisdictions including • The 9,314,450 patent c
Slide 15: Dimerix receptor-HIT platform
Dimerix receptor-HIT platform For personal use only Receptor-HIT • Patented tool that enables understanding of receptor interactions • Particularly suited to G-Protein Coupled Receptors (GPCRs) – most targeted receptor class for drug discovery • Can identify new uses for existing drugs and drive the
Slide 16: Key takeaways – Dimerix Limited
Key takeaways – Dimerix Limited (ASX: DXB) For personal use only 1. Strong track record in delivering regulatory, patent and clinical milestones 2. Two Phase 2 trials in kidney diseases about to commence, as a follow up to last year’s Phase 2a trial, where compelling clinical data was seen 3. Signif
Slide 17: Contact
For personal use only Contact Kathy Harrison Chief Executive Officer + 61 419 359 149 kathy.harrison@ dimerix.com Dimerix Limited ACN 001 285 230 www.dimerix.com